Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3042% below fair value
$1.52−0.08 (-5.00%)
Close on Nov 18, 2026Market cap $12.53MP/E –Yield –
Lipocine net income
Net income is the profit left for shareholders after every expense, interest and tax.
Lipocine's net income for the twelve months ending Jun 30, 2026 was -$11.85M. For fiscal 2025 it was -$9.63M, down 115371.9% from the year before. The highest annual figure on record is $3.89M in fiscal 2012.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.63M | -115371.9% |
| FY2024 | Dec 31, 2024 | $8.35K | – |
| FY2023 | Dec 31, 2023 | -$16.35M | – |
| FY2022 | Dec 31, 2022 | -$10.76M | – |
| FY2021 | Dec 31, 2021 | -$634.40K | – |
| FY2020 | Dec 31, 2020 | -$20.96M | – |
| FY2019 | Dec 31, 2019 | -$13.01M | – |
| FY2018 | Dec 31, 2018 | -$11.66M | – |
| FY2017 | Dec 31, 2017 | -$20.98M | – |
| FY2016 | Dec 31, 2016 | -$18.97M | – |
| FY2015 | Dec 31, 2015 | -$18.21M | – |
| FY2014 | Dec 31, 2014 | -$20.37M | – |
| FY2013 | Dec 31, 2013 | -$10.59M | -372.5% |
| FY2012 | Dec 31, 2012 | $3.89M | – |
| FY2011 | Dec 31, 2011 | -$5.16K | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.62M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.67M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.37M | -233.0% |
| Q3 FY2025 | Sep 30, 2025 | -$3.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.86M | -153.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.78M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.22M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.07M | – |
| Q1 FY2024 | Mar 31, 2024 | $3.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.28M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.55M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.87M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.23M | -117.7% |
| Q3 FY2022 | Sep 30, 2022 | -$2.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.63M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.49M | – |
| Q4 FY2021 | Dec 31, 2021 | $12.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.81M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.51M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.31M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.77M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.29M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.06M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.43M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.22M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.23M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.46M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.26M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.72M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.33M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.70M | – |
| Q2 FY2017 | Jun 30, 2017 | -$6.09M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.86M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.97M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.24M | – |
See a number that looks wrong?